BiomX

BiomX

Customized phage therapies to eradicate harmful bacteria in chronic diseases.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

round
investor

€0.0

round
investor investor investor investor investor investor investor investor investor investor investor

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor investor investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
*
N/A

$40.0m

Post IPO Debt
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
EBITDA0000000000000000000000000000
Profit0000000000000000000000000000
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article, Equity research estimates

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by BiomX

Edit
Adaptive Phage Therapeutics
ACQUISITION by BiomX Mar 2024
RondinX
ACQUISITION by BiomX Dec 2017